7-29-05

PATENT
Application S/N 10/741,929
Docket No. 202.2D6
Date: July 27, 2005

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL

Sir:

Transmitted herewith for filing is an information disclosure statement by Applicants.

For: **PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS - 6**

Enclosed are:

(X) Supplemental information disclosure 25 references.
(X) Copies of 25 references (non-U.S. patent or patent publication) cited in the IDS.
(X) Certificate of mailing by express mail (label No. EV 205131207 US).
(X) Return postage prepaid postcard.

The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**. Small entity status has previously been claimed for this application.

Please use **Customer No. 26,551** for the correspondence address.

Date: July 27, 2005

Daryl D. Muenchau

Daryl D. Muenchau
Registration No. 36,616
Attorney of Record
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-587-9333

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY EXPRESS MAIL

Attorney Docket No.	:	**202.2D6**
Applicant(s)	:	**Clarence N. Ahlem, et al.**
Application Serial No.	:	**10/741,929**
For	:	**Pharmaceutical Compositions and Treatment Methods - 6**
Attorney	:	**Daryl D. Muenchau Registration No. 36,616**
Express Mail Label No.	:	**EV 205131207 US**
Date of Deposit	:	**July 27, 2005**

I hereby certify that the accompanying:

transmittal form, supplemental information disclosure statement for Serial No. 10/741,929 listing 25 references, copies of 25 references cited in the IDS, return postage prepaid postcard and amendment and response to restriction requirement

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on July 27, 2005 and are addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda Mannon

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE December 19, 2003	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		H6-279488	10-04-94	Japan			X	

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
		Bruder, S. P., et al., Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy, *J Cell Biochem*, 56(3), pp. 283-94, 1994
		Chen, Z.et al., Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. *J. Clin. Invest.* 103, pp. 401-406, 1999
		Fink, B. E. et al., Novel structural templates for estrogen-receptor ligands and Prospects for Combinatorial Synthesis of Estrogens. *Chem. Biol.*, 6, pp. 205-219,1999
		Gao, H. et al., Comparative QSAR analysis of estrogen receptor ligands, *Chem. Rev.*, 99, pp. 723-744, 1999
		Grundy, J., Artificial Estrogens. The Technical College, Acton, London, W.S., England, pp.281-416, May 1956
		Jilka RL, et al., Increased osteoclast development after estrogen loss: mediation by interlekin-6, *Science* 257, pp. 88-91, 1992

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
		Jilka, R.L. et al., Increased bone formation by prevention of osteoblast apoplosis with parathyroid hormone, *Journal of Clinical Investigation*, 104(4), pp 439-446 August 1999.
		Khosla, S. et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. *J. Clin. Endocrinol. Metab.* 83, pp. 2266-2274, 1998
		Lea, C.K. et al., Androstenedione treatment reduces loss of cancellous bone volume in ovariectomized rats in a dose-responsive manner and the effect is not mediated by estrogen, *J. Endocrinol.*, 156, pp. 331-339, 1988
		Ojasoo, T. and Raynaud, J. P. Unique steroid congeners and receptors studies, *Cancer Res.*, 38, pp. 4186-4198, 1978
		Oursler M. J., Estrogen regulation of gene expression in osteoblasts and osteoclasts *Critical Review in Eucaryotic Gene Expression*, 8:125-140 1998
		Picherit, C. et al., Dihydrotesterone prevents glucocorticoid-negative effects on fetal rat metatarsal bone *in vitro*, *Biol. Neonate*, 77:181-190 2000
		Pietras, R.J. and C.M.Szego. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. *Nature*, 265, pp.69-72, 1977
		Plotkin, L.I., et al., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, *J. Clin. Invest.* 104(10):1363-1374 November 1999.
		Pomper, M. G., et al., 11β-Methoxy-, 11β-ethyl- and 17α-ethynyl-substituted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. *J. Med. Chem.*, 33, pp. 3143-3155, 1990
		Riggs, B, et al. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis, *J. Clin. Invest.*, 51, pp.1659-1663, 1972
		Santoro, N.F., et al, Therapeutic controversy: Hormone replacement therapy-where are we going? *J. Clin. Endocrinol. Metab.* 84, pp.1798-1812, 1999
		Scheven B.A., et al, Dehydroepiandrosteone (DHEA) and DHEA-S interact with 1,25-dihydroxyvitamin D_3 ($1,25(OH)_2D_3$) to stimulate human osteoblastic cell differentiation Life Sciences, 62, pp. 59-68, 1988
		Solmssen, U. V., Synthetic estrogens and the relation between their structure and their activity. *Chem. Res.*, 37, pp. 481-598, 1945
		Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7α,11β-Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. Bioorg. Med. Chem. Lett., 7, 2919-2924 1997
		Tobias, J.H., et al. , 5α-dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, *Am. J. Physiol. Endocrinol. Metab.* 267, pp. E853-E859, 1994.
		Watts, N. B., Clinical utility of biochemical markers of bone remodeling, *Clin. Chem.*, 45, pp. 1359-1368, 1999
		Weinstein R.S. et al., Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids *J. Clin.Invest.* 102, pp. 274-282, 1998
		Weinstein RS et al., The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage, *Endocrinology* 138, pp. 4013-4021, 1997

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.